Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call. [Operator Instructions]. This call is being recorded on Tuesday, May 6, 2025. I would now like to turn the conference over to Kellen Sanger, SOPHiA GENETICS Head of Strategy and Investor Relations. Please go ahead.

Thank you, and good morning, everyone. Welcome to the SOPHiA GENETICS First Quarter 2025 Earnings Conference Call. Joining me today to discuss our results are Dr. Jurgi, our Co-Founder and Chief Executive Officer; Ross Muken, our company President; and George Cardoza, our Chief Financial Officer. I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release issued by SOPHiA GENETICS today and in the documents and reports filed by SOPHiA GENETICS from time to time with the Securities and Exchange Commission. During this call, we will present both IFRS and non-IFRS financial measures. A reconciliation of IFRS to non-IFRS measures is included in today's press release, which is available on our website. With that, I'll now turn the call over to Jurgi.

Thanks, Kellen, and good morning, everyone. I will start today's call with a brief recap of Q1 performance, which came in slightly ahead of our expectations as growth reaccelerated and cost management continues to improve. I will then turn the call over to Ross, who will give a more detailed update on the business. George will close with a review of our Q1 financial performance before we take your questions. Last quarter, we highlighted that 2024 was a foundational year for SOPHiA. We laid the groundwork for accelerated growth in 2025 by signing an impressive cohort of new customers, continuing to penetrate the U.S. market, and launching new and exciting applications such as MSK ACES and MSK Impact. In Q1, these efforts began to materialize. Revenue grew 15% on a constant currency basis and 13% on a reported basis, representing a solid movement toward near historical growth levels. Going forward, we expect to deliver accelerating revenue growth along the 3 drivers we outlined at the beginning of the year. First, we will capitalize on new customer signings by expediting implementation times and expanding across those new accounts over time. In 2024, we signed an impressive 92 new core genomic customers and in Q1 2025, we added 28 new customers to that total. Our focus continues to be on implementing these new customers as quickly as possible so that they begin generating revenue faster. We implemented 33 new customers in the first quarter, up from an average of 23 per quarter last year. I look forward to these customers ramping up usage over the next few months and adopting additional applications over time. The second growth driver we will continue to focus on is the U.S. market. In Q1, revenue and analysis volume from U.S. core genomic customers grew over 30%…

Thanks, Jurgi. The go-to-market team share your excitement and confirm there is broad and growing demand for the SOPHiA offering. Along those lines, I'll start today by giving a brief update on our first quarter performance, including a strong start to the year across both new and existing business. I'll then cover some of the broader market dynamics before closing with a look at what we're seeing in the pipeline. First, the core business returned to healthy levels as revenue grew 15% on a constant currency basis in the first quarter despite biopharma continuing to present some modest headwinds. We are proud to have reaccelerated the growth engine of the core business, and the biopharma pipeline is again developing well. On the clinical side, from a regional perspective, North America and Asia Pacific continued to outperform in Q1 with 32% and 40% year-over-year volume growth, respectively. Latin America declined slightly due to the acquisition of one of our top customers in the region by another lab, which we covered in detail in 2024. EMEA volume growth remains solid, with the United Kingdom as a notable driver. Last year, we announced a series of new customer signings across the U.K., including 5 of the 7 NHS genomic laboratory hubs adopting SOPHiA DDM. Due to these signings and others, U.K. analysis volume grew over 60% year-over-year, and U.K. revenue was up approximately 80%. From an application standpoint, we continue to establish ourselves as a global leader in HemOnc testing. HemOnc volumes grew 34% year-over-year in the first quarter off an increasingly large base. With over 180 HemOnc customers globally, we believe we are one of the largest providers of blood-based cancer testing in the world, an area of critical importance to both our clinical and biopharma constituents. We are confident HemOnc will…

Thank you, Ross, and good morning, everyone. As Jurgi and Ross highlighted, Q1 results came in slightly ahead of expectations as new business from 2024 begins to come online. Total revenue for the first quarter of 2025 was $17.8 million compared to $15.8 million for the first quarter of 2024, representing year-over-year growth of 13%. On a constant currency basis, year-over-year revenue growth was 15% as foreign exchange headwinds negatively impacted reported revenue by approximately $400,000. Platform analysis volume was approximately 93,000 for the first quarter of 2025 compared to approximately 84,000 for the first quarter of 2024, representing year-over-year growth of 11%. Core genomic customers were 490 as of March 31, up from 463 in the prior year period and up sequentially by 18 customers relative to Q4 2024. While we added 33 new customers in the quarter, we churned out a few smaller accounts who had not generated revenue over the past 12 months. Nonetheless, Q1 revenue churn remained low at approximately 4%, which is in line with our historical averages. Net dollar retention for the quarter was 103%, driven primarily by the decline in growth in Latin America. Gross profit for the quarter was $12.2 million compared to gross profit of $10.4 million in the prior year period, representing year-over-year growth of 17%. Gross margin was 68.7% for the first quarter of 2025 compared with 65.9% for the first quarter of 2024, up 273 basis points year-over-year. Adjusted gross profit was $13.4 million, an increase of 21% compared to adjusted gross profit of $11.1 million in the prior year period. Adjusted gross margin reached a record high of 75.7% for the first quarter of 2025, up 520 basis points from 70.6% in the first quarter of 2024. As Jurgi mentioned, targeted platform improvements throughout the year continue…

Thank you, George. I am proud of what the team achieved this quarter. We took a major first step during Q1, accelerating revenue growth to 15% constant currency, expanding adjusted gross margins again, now up to 75.7% and improving adjusted EBITDA by 24% year-over-year. The quarter sets the tone for a strong 2025. Looking ahead, bookings momentum remains strong and end markets continue to grow. Our offering sits at the center of concentric trends in health care. We have built an expansive global network of customers and dynamic AI capabilities, which generate critical insights for a growing number of cancer and rare disease patients globally. Better therapies are being developed each day and data-driven medicine has become new basis for diagnosis, therapy selection and follow-on testing in addition to drug development and deployment. Given our business sits at the center of these innovations, we remain confident on our long-term growth. In closing, I want to say thank you to our SOPHiA colleagues, partners, customers and investors for joining us in our journey to transform patient care with data-driven medicine. Please note, we are presenting at the RBC Conference on May 20 and 21 in New York City. We all look forward to continuing to update you on SOPHiA's future success of democratizing data-driven medicine around the world. Operator, you may now open the line for questions.

[Operator Instructions] Your first question comes from the line of Bill Bonello with Craig-Hallum. Please go ahead.

Good morning guys, nice quarter. Just a couple of follow-up questions. First, you talked about accelerating the time frame for implementation, and we are seeing that in the good implementation numbers. Can you talk just a little bit about the kinds of actions that you've been able to take that actually allow you to implement more quickly than maybe you have been able to do so in the past?

Yes. Thank you, Bill. So indeed, right, to start with the numbers first. As we highlighted this quarter, we implemented 33 new customers versus an average of 23 customers per quarter for 2024. And obviously, this is as well the result of bookings that have been improving over time. So specifically on the implementations, Ross has been scaling up team capabilities, and we'll give you a bit more color.

Thanks, Bill. So obviously, this has been a big focus. All of last year, we spoke to you about accelerating bookings momentum. And so obviously, we knew that, that would yield some pressure on the implementation teams as the both number of implementations were going up and also the complexity. So you can see our deal size is going up. And so with that, also, these are more complicated, particularly liquid biopsy implementations. And so we have created some tooling and automation and different aspects of the process to enable us to better execute and speed up elements. And also, we've -- I would say, from a process perspective, added in some industrialization to make sure that at different stages, we understand sort of how much time and stage should be, what do we do to troubleshoot if there's challenges in the lab. We've increased a little bit our headcount in terms of some of the wet lab and field application scientists that go into the field in the labs and work hand-in-hand with the clinicians, right? Because obviously -- sorry, with the pathologists because obviously, there's a complexity to some of these capabilities. And so I think between tooling and systems process and then some select headcount, we've been able to speed up this process materially.

Okay, that’s really helpful. And then just my second one is -- you talked about the average contract value increasing. And certainly, we would expect that with the more complicated analysis that are coming on board. But you also talked about enterprise sales. And first of all, I want to make sure I understand that right. I'm assuming you're talking about customers that are coming on and instead of just coming on initially with 1 or 2 applications, they're essentially using DDM for all of the NGS testing that they're doing. But can you, first of all, clarify if that is what you mean by enterprise sales? And then if so, why you think you might be seeing an uptick in that? Is that -- is there something changing in the overall environment that's making it just that much more difficult for clients to do the bioinformatics on their own? Or is there a specific push that you've been making as a company to try and sell sort of at the enterprise level? Maybe just elaborate a bit on that.

Yes. Sure, Bill. So I will start and then let Ross further develop. So indeed, as you know, our platform has multiple capabilities, right, for multiple disease areas, hung, solid tumor, hereditary cancer, liquid biopsy and rare neuro disorders. And for each of these areas, our platform can be used for multiple type of applications, multiple type of test kits. So today, it's 58% of our customers who are using two or more applications. So definitively, there is room to expand the utilization of applications per customer. And you're absolutely right in your understanding of the enterprise concept. These are deals where when we get in, we're basically signing for a majority of all the applications they are covering, right, unlike when we are landing a customer only for liquid biopsy. So Ross, maybe you want to give a bit more color on what you're seeing, especially when it comes to the bioinformatics in the field and the guide Bill, whether the ACV being doubled year-on-year on a contract basis will primarily come from that or from more complex solutions or a mix?

Thanks, Jurgi. And it's a really good question, Bill. This is probably one of the most important dynamics of what's happening in market. And it really speaks to a point Jurgi touched on and you made around the complexity of what is being analyzed now in many laboratories. And so if you think about the evolution of the market as we've gone from single gene to multi-gene or pan tumor and then more complex capabilities like CGP exome, whole genome, MRD, etcetera. Now many laboratories have multiple type of sequencers, multiple type of assays or chemistry they are running, maybe different automates and a mix of homegrown and then maybe SOPHiA or other solutions, right? And as the complexity continues to go up, it becomes completely unmanageable from an efficiency and cost perspective, particularly as data is growing, let's say, north of 50% in terms of output in many of these laboratories. And so the desire to then simplify across the workflows and harmonize on a common platform will gain you massive leverage in your laboratory where many still are, I would say, human capital constrained. And so that's really playing to our strength, particularly with our universal library prep and then with the uniformity of our workflows around different applications. And so this is attracting more and more laboratories to basically sunset either existing homebrew solutions and/or consolidate competitor solutions to us. And we think this will only accelerate as we have more examples of this. Obviously, in Q1, we called out Jessa, very large lab in Belgium. This is a great example, but we will have many more over the coming quarters. If I look at my pipeline, the number of multi-application deals is up materially year-on-year, and this is quite important. I would say, on top of…

Excellent. Thank you so much.

And your next question comes from the line of Conor McNamara with RBC Capital Markets. Please go ahead.

Hey guys thanks for taking the questions and congrats on a solid quarter. Just on the gross margins, they came in a lot stronger than anticipated. Was there anything onetime in there? Or are these gross margins sustainable above 75% going forward?

Hey good morning Conor. So first, maybe you remember that we've been continuously speaking on improving as well our algorithms, right? So that while the data compute becomes more intense, the efficiency of the algorithms will become as well better and better. And so to some extent, this is being materialized as well in the gross margin, but I will let George further develop.

Yes. We did have a relatively favorable mix in the first quarter. So I do think gross margin did come in on the high side in the first quarter. We said year-over-year, they would be up sequentially, and we still believe that. But I do think the first quarter margin was probably a little bit better than expected. Again, we had a couple of onetime items in there, but I do think ultimately, you will see it still improve on a year-over-year basis, although not quite this high in the out quarters.

Great, thanks George. And then on the BioPharma side of the business, is there any large contract wins or large contribution considered in your guidance? And where is the biggest medium-term opportunity that you're seeing with biopharma? Is it an early drug discovery and development? Or are you starting to see a lot more interest on the targeted medicine companion diagnostics side from your BioPharma customers?

So yes, thanks for the question, Ross, Conor. So Ross was just at the AACR conference, right, which is one of the biggest conference around cancer research. So he's going to let you know where we stand today.

Thanks, Jurgi. So Conor, as you recall, we did a bit of changes in our BioPharma business last summer. And with that, we've seen a material improvement in pipeline. And now in this quarter, you're starting to see bookings come through. And so I think in general, we're quite pleased with the progress we've made, particularly in CTAs, CDx and sponsored testing sort of more on the traditional diagnostic side of things. I think the reality is we have shown good momentum. We are quite pleased with the progress. We are where we expected to be on that side of the business, but I would say, in general, obviously, this is still in its nascent stages as a business. And so from that perspective, we are aggressively pursuing business, but I'll let George maybe comment on how we're reflecting that in the guidance.

Yes. We guided before that we expected pharma to be flat in 2025. So even though we're very excited about some of the opportunities in the pipeline, at least at this point, we are expecting pharma to be flat year-over-year and then ideally a significant benefit in 2026.

Got it, thanks. And just last one for me. I appreciate the color you guys gave on the tariff impacts and kind of what's going on from a macro environment. But is there a medium-term opportunity for you guys just because you're not selling capital to customers where either your customers may be looking to maximize the capital investments they've made or if they were considering building out an offering -- a software offering on their own that required a larger investment, you may be able to pick up some of that business just because they're trying -- they're maybe budget constrained or trying to save money on any capital expenses, and that's all I've got. Thanks for the questions.

Yes. Thank you, Conor. So indeed, right, it looks like there is a trend on being, I would say, to some extent, constrained on CapEx investments, obviously, in the world of research activities, maybe to some extent in the world of hospitals, but as you know well, we are diagnostics, right? We are not tools so we don't sell as a CapEx. We go into the OpEx of the hospitals who are being paid on news. So I would say, today, we don't see a pressure, and to your point, this might be an opportunity as well, right, because it could be that some hospitals or reference labs, given those new dilemma, don't want to invest themselves on making their own developments, and they want to use a software like SOPHiA. Ross, we've been interacting with a number of customers around those constraints recently. Maybe you want to highlight where we stand and I guess, the little friction we see on our side.

Yes. So, and maybe just to be super clear, we today see very healthy budgets across our customers. So in general, it's quite a solid environment for us, essentially in most geographies, around the world, so in general, it's quite strong. I would say probably the biggest immediate or near-term impact we are seeing is if you have bought a sequencer, right, and upgraded, you have great desire to fill, right, those flow cells. And so that means more applications, more content, which means players like SOPHiA need to step up and provide you with menu to be able to make the economics of that purchase viable. And so increasingly, you see those interactions benefiting us. And it's also brought us closer to some of the cap equipment players as I think a number of them see us, right, as a key partner to bring that menu and to bring the validation and to show the ROI so that when you're bringing in-house certain capabilities, you can show that, that level of investment was prudent and that you can ultimately not just bring, obviously, care closer to the patient and improve turnaround times, but you can drive a financial benefit and an ROI, which is obviously critical for CapEx investment in the current environment. So again, I think it's a net positive for us.

Great. Thanks for all that color.

And your next question comes from the line of Tejas Savant with Morgan Stanley. Please go ahead.

Hi, this is Jason [ph] on for Tejas. Thank you for taking our questions. So maybe just to start off a question on the collaboration with AstraZeneca. So you originally began this collaboration with AstraZeneca in 2023. Could you just talk about the traction you've had from this collaboration in that time frame? What has it meant for the company's volume and ASP profile? Also, does this new collaboration include MSK-IMPACT? And if not, could including MSK-IMPACT be in the cards? And how are you thinking about other collaboration opportunities in the future, in particular, with large pharma? Thank you.

Yes. Thank you, Jason. I will start and then let it to Ross. So as you may remember, our partnership with AstraZeneca on the diagnostic side started with HRD testing, which was something that the market was missing for prescription of PARP inhibitors, right? So this was our initial collaboration, where we had worked together on market access needs so that more patients could be properly tested in Europe on HRD. And then this collaboration was expanded to your point, with MSK-ACCESS and MSK-IMPACT. Ross, do you want to give a status on where we stand on ACCESS IMPACT and the new collaboration agreement we just signed?

Thanks, Jurgi. And Jason, thanks for the question. So I would say, one, it's great to be aligned with AZ around these efforts, given, obviously, they today have an incredibly robust pipeline and one that matches very well with our offering in menu, right? So there's a ton of fantastic overlap between the two organizations and our missions, and they obviously have a real desire as well to bring care closer to the patient, improve market access, and we're happy to help them on that journey, so it's a really good partnership up and down in the organization. Now if you look at the success we have had with ACCESS and now IMPACT, obviously, they as well as our own efforts have been really critical to getting that into as many labs as we've penetrated quickly, right? So I would say this is probably for the company, one of the fastest and best new product launches in history, and so in that vein, obviously, some of their efforts have helped us there, so we're really appreciative of the partnership. From that standpoint, you can see the recent expansion is kind of evidence of the success, right? And so we expect that to bear very nice fruit over the - not just upcoming periods, but over the next several years. This is really a key partnership and product for us. Now I am also pleased to say, as I hinted at before, we've also expanded our outreach with other top pharma and we will have, hopefully, later this year, some further disclosures. But I think you can sort of ascertain that there are others as well that see the world similar to AZ and see the value that SOPHiA can bring, particularly around CGP testing and liquid biopsy, and so we expect this now to broaden out to others. We publicly talked a bit about J&J as an increasing, I would say, important other partner for us, but I think there will be more. And so again, as Jurgi mentioned, coming off of World CDx and AACR, we really have seen an uptick in interest and now we've got to translate that obviously into bookings and revenue. And so again, we've been conservative, as George stated in our assumptions for this year, but I'm quite confident that the trajectory is pointing in the right direction for us.

Great. That was helpful. Then maybe as a follow-up question, a question on the balance sheet. So, I guess last quarter, SOPHiA, you reframed your adjusted operating profitability target from year-end 2026 to adjusted EBITDA breakeven in 2027. So, is the current balance sheet sufficient to reach this new target? And how are you thinking about opportunities to strengthen the balance sheet? Thank you.

Yes. George, that's for you.

Yes. No, again, we finished the quarter with $68 million in cash plus another $35 million in undrawn credit line. So, that's a total of over $100 million of available liquidity. Very pleased that we continue to shrink our EBITDA losses, and I think you have seen all the work and the efforts we have done around expense control and improving our gross margins on the COGS side and again, our loss was less than $10 million this quarter. So certainly, I think that frames us up fairly well. And again, we think our losses will be quite small by the end of 2026, and we will cross over into adjusted EBITDA profitability into 2027.

Great. Congrats on the quarter.

And your next question comes from the line of Daniel Brennan with TD Cowen. Please go ahead.

Hey good morning guys. This is Kyle [ph] on for Dan. Thanks for taking the questions. I wanted to go back to the guide and sort of pacings. You reiterated the guide this year and the implementations were pretty strong in the first quarter. Does this change any of the -- I mean, I know you're still guiding for a back half weighted year, but does this sort of smooth out some of that back half weighting since implementation has been stronger?

Yes, George?

Yes. No, we're still expecting, while we're pleased certainly with first quarter results, we think it is prudent to maintain the guidance at this point and we do still feel, again, given our contracts that we've signed that are still haven't really transferred into routine, that will happen more in the back half of this year. So, we do think we're going to see more growth in Q3 and certainly in Q4. And clearly, in the first quarter, our revenue growth was within the 10% to 17% guidance range that we established so, at this point, we are maintaining our guidance.

Got it. And then is there any detail you're willing to provide on the new customer signings? What percentage of the new signings are U.S. versus OUS? And earlier, you talked about the average size of contracts getting bigger. Can you quantify that at all?

Yes, we can give you some more color on the new logos in terms of the number of logos where they come from. As you know, we don't disclose dollar values of bookings, right? So, Ross, on new logos?

Yes. Thanks, Jurgi. So, in terms of the new customer signings, obviously, we've had, frankly, success around the globe. But I would say there is sort of notable strength coming in North America. And as you think about this year and into next year, I do think relative to our revenue mix, a disproportionate amount will come from the U.S. and those tend to be much larger lands or expands, several times larger than our average. So that is pulling up that ACV number. And I think that number which again doubled year-on-year, will continue to trend favorably for the remainder of the year. So, I would say, in total, this will obviously show up eventually in our North American revenue growth, which on the clinical side was quite robust in the first quarter, and we expect to be strong throughout the year. But I can tell you the dynamics in general are really strong in terms of the U.S. business, and we're really pleased where that is. And we think, again, this will be one of the key growth drivers for us in the back half of the year and into 2026.

Got it. Thanks, guys.

Your next question comes from the line of Subbu Nambi with Guggenheim. Please go ahead.

Hey guys, good morning. Thank you for taking the questions. You churned out a few smaller customers who weren't contributing revenue. So, we were wondering what is the split on customer number who aren't material contributors versus those who are?

Ross?

Yes. So Subu, so obviously, as you think about different regions, right, obviously, an IDN or an AMC in the U.S. or U.K. or even France is going to be quite different than someone in Costa Rica or in Thailand or Malaysia, etcetera, right? So, I would say, in total, it's sometimes challenging, particularly in more of the emerging markets to know when we sign a customer what the full potential is but I would say, increasingly, again, and this is around this ACV comment, we've been more focused on, let's say, the top 500 sort of cancer centers in the world. And there, obviously, we know the size and we know the patient sort of levels. And so I think, again, you'll probably see some dynamic change in that mix, but again, when you're running a network model and the diversity of what we have, you're trying to play for the broadest network. And so we'll continue to obviously entertain customers in all of these emerging markets for oncology. But obviously, it will at times lead to at least the churn customer number being elevated, but not the churn percentage. We're still very pleased with where that remains in the low single digits, which is a world-class number for software.

That's awesome. Can you provide some color on cross selling the MSK-ACCESS and MSK-IMPACT offerings? I know MSK-ACCESS had 34 adopters as of February 2025. I'm just wondering how many adopters of both assays do you have today?

Yes. Thank you, Subbu. So indeed, MSK-ACCESS and MSK-IMPACT are, we believe, applications, which have a bright future, but it's still pretty early, yes. So on MSK-ACCESS, the launch has been successful. We have had adoption of MSK-ACCESS in all continents, as you said, for about 30 customers already and we expect basically the numbers to really pay out as we progress and we get more and more utilization. But I would say we're still very much at the beginning and with a decentralized solution that everyone can adopt, probably MSK-ACCESS is pretty unique in its category. So we have high expectations, but still work to do so that on the market access side, we see more and more volume adoption. When it comes to MSK Impact, say the competitive landscape is different. You already had some people that adopted comprehensive genomic profiling solutions in the market. So the market already exists, more competitive, but the capabilities of MSK-IMPACT because of its nature with tumor normal are pretty unique. And so there, we are as well very confident that in conjunction with MSK-ACCESS, we will have a number of customers that is going to grow in the adoption of MSK-IMPACT. The two tends to go very well together, MSK-IMPACT for the first diagnosis and after MSK-ACCESS for the longitudinal follow-up of the patient as the patient is being treated.

Helpful, Jurgi. And one last one. You guys announced the expanded agreement with AstraZeneca to increase the number of MSK-ACCESS adopters from 20 to 30 this year. Was this already contemplated in your guide given you didn't raise your guidance today? Or if not, would completing this just present an upside to the guide? Or is the time frame about committing to adopt the solution and not necessarily ramping up and gene writing revenue?

George?

Yes. Again, when we sign somebody for MSK Access, I mean, it is a rather detailed application, and a lot goes into the validation and bringing it live. So it does have probably a little bit longer of a runway in terms of somebody signing a contract to actually going live, but we're still quite bullish about the opportunities here going forward.

Got it. Makes sense, thank you guys.

And your next question comes from the line of Mark Massaro with BTIG. Please go ahead.

Hey guys, this is Vivian [ph] on for Mark. Thanks for taking the questions. I'll just keep it to one actually. So just on your competitor fabric recently being acquired, I know the revenue base is much less mature, but could you just share any new views on how you're thinking about the competitive landscape? I think in the past, you've also called out increasing mix shift to exome applications. So just any views there? Thanks.

Yes. Thank you, Vivian. So I guess this acquisition highlights the value of data analytics and bioinformatics, right? And we have been often speaking about the fact that over time, probably data production, although there is utility on pre-sequencing steps would become more and more automated and that knowledge and dollars would move more towards data analytics. So I would say this definitively highlights, in my opinion, the value of data analytics recognized in that case by GeneDx. And indeed, 20% of our business is on rare disorders where with one of the applications called Enhance Exome, we're seeing a significant demand in the market.

Great. Thanks for taking the question.

No further questions at this time. I would like to turn it back to Jurgi Camblong for closing remarks.

So thank you all for the questions and looking forward to update you in the next event or soon in an event in New York, ready to meet investors. Have a good day.

This concludes today's conference call. Thank you all for joining. You may now disconnect.